Marshall Wace, LLP Immunity Bio, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 240,311 shares of IBRX stock, worth $778,607. This represents 0.0% of its overall portfolio holdings.
Number of Shares
240,311Holding current value
$778,607% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding IBRX
# of Institutions
213Shares Held
71.2MCall Options Held
1.64MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA17.3MShares$56.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$37 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$28 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.84MShares$12.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$7.28 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.3B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...